Drugs / Atuveciclib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02345382 | Feb 2015 → Sep 2016 | leukemia | Bayer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atuveciclib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02345382 ↗ |
| Known as | BAY1143572 | “Atuveciclib, BAY1143572” NCT02345382 ↗ |
| Modality | Small molecule | — CHEMBL4439321 ↗ |
| Route | Oral | “20 milligram (mg) BAY1143572 tablet orally once daily” NCT02345382 ↗ |